

IACH 2021 Scientific Program
All timing in CEST

Friday, September 24, 2021	
12:45-13:00	Welcome: Mohamad Mohty , France & Arnon Nagler , Israel
13:00-14:50	Opening Session: State of the art therapy in ...
13:00-13:20	CLL: Arnon Kater , Netherlands
13:20-13:40	CML: Giuseppe Saglio , Italy
13:40-14:00	Hodgkin lymphoma: Ali Bazarbachi , Lebanon
14:00-14:20	Mantle cell lymphoma: <i>TBA</i>
14:20-14:50	Panel Discussion
14:50-15:00	<i>Break</i>
15:00-16:50	Session 1: Immunotherapy
15:00-15:20	Immune modulation prior and post HSCT for AML: Gesine Bug , Germany
15:20-15:40	TCR Engineering: Fabio Ciceri , Italy
15:40-16:00	Anti-virus CTLs: May Daher , USA
16:00-16:20	Gamma/delta T cells: Jurgen Kuball , Netherlands
16:20-16:50	Panel Discussion
16:50-17:00	<i>Break</i>
17:00-18:50	Session 2: Transplant indications in ...
17:00-17:20	AML: Arnon Nagler , Israel
17:20-17:40	ALL: Sebastian Giebel , Poland
17:40-18:00	MF: Ibrahim Yakoub-Agha , France
18:00-18:20	MDS: Corey Cutler , USA
18:20-18:50	Panel Discussion
18:50-19:00	IACH Award Ceremony Mohamad Mohty , France & Arnon Nagler , Israel
19:00-19:30	ALL – Progress in research and Therapy in 2021: Hagop Kantarjian , USA
19:30-21:00	The role of modern agents for relapsed/refractory myeloma CME-accredited symposium Moderator: Mohamad Mohty , France
19:30-19:40	Introduction: latest advances in myeloma therapy: Mohamad Mohty , France
19:40-19:55	Mechanism of action of XPO inhibitors: Nizar Bahlis , Canada
19:55-20:10	The case for XPO1 inhibitors: <i>TBA</i>
20:10-20:25	The case for Venetoclax: Rafael Fonseca , USA
20:25-20:40	The case for Melflufen: <i>TBA</i>
20:40-21:00	Panel Discussion

Saturday, September 25, 2021	
09:00-11:20	Session 3: Advances in transplant complications
09:00-09:20	Acute GVHD: Iskra Pusic , USA
09:20-09:40	Chronic GVHD: Zinaida Perić , Croatia
09:40-10:00	CMV infection at the era of letermovir: Bipin Savani , USA
10:00-10:20	Endothelium-related complications: Selim Corbacioglu , Germany
10:20-10:40	EBV-PTLD: Rafael de la Cámara , Spain
10:40-11:20	Panel Discussion
11:20-11:30	<i>Break</i>
11:30-13:20	Session 4: Advances in AML therapy
11:30-11:50	The case for CPX-351: Pau Montesinos , Spain
11:50-12:10	The case for oral azacytidine: Amer Zeidan , USA
12:10-12:30	The case for venetoclax: Fahrad Ravandi , USA

12:30-12:50	The case for Flt3 inhibitors: Jordi Esteve , Spain
12:50-13:20	Panel Discussion
13:20-13:30	Break
13:30-14:15	Optimising the management of hepatic VOD: utilising the tools available to improve patient outcome <i>Industry Symposium</i>
14:15-15:00	Treating high-risk AML* in the real world <i>*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AMC-MRC)</i> <i>Industry Symposium</i>
15:00-15:30	Your questions answered live: latest real-world evidence in high-risk AML* with Professor Cluzeau <i>*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)</i> <i>Industry Meet the Expert Session</i>
15:00-15:30	Break
15:30-17:20	Session 5: Advances in rare entities
15:30-15:50	BPDCN: Naveen Pemmaraju , USA
15:50-16:10	Mastocytosis: <i>TBA</i>
16:10-16:30	Aplastic anemia: <i>TBA</i>
16:30-16:50	Waldenstrom disease: Meletios-Athanasios Dimopoulos , Greece
16:50-17:20	Panel Discussion
17:20-17:30	Break
17:30-18:30	The hard-to-treat lenalidomide relapsed/refractory patients CME-accredited symposium Moderator: Mohamad Mohty , France
17:30-17:50	Carfilzomib-based combinations: Thomas Martin , USA
17:50-18:10	Pomalidomide-based combinations: Fredrik Schjesvold , Norway
18:10-18:30	Panel Discussion
18:30-20:30	Session 6: Bispecific antibodies and antibody-drug conjugates in ...
18:30-18:50	Lymphoma: Gilles Salles , USA
18:50-19:10	Myeloma: Salomon Manier , France
19:10-19:30	AML: <i>TBA</i>
19:30-19:50	ALL: Eolia Brissot , France
19:50-20:30	Panel Discussion

Sunday, September 26, 2021

09:00-10:50	Session 7: State of the art in HSCT
09:00-09:20	Optimizing stem cell collection: Christian Chabannon , France
09:20-09:40	PtCy for GVHD prophylaxis: Didier Blaise , France
09:40-10:00	Optimal choice of donor: Annalisa Ruggeri , Italy
10:00-10:20	Bloodless HSCT: Bhagirathbhai Dholaria , USA
10:20-10:50	Panel Discussion
10:50-11:00	Break
11:00-12:00	Latest advances in chronic GvHD CME-accredited symposium Moderators: Mohamad Mohty , France & Arnon Nagler , Israel
11:00-11:20	Diagnosis and grading of chronic GVHD: Daniel Wolff , Germany
11:20-11:40	Management of steroid refractory chronic GVHD: a focus on belumosudil: Aleksandr Lazaryan , USA
11:40-12:00	Panel Discussion
12:00-13:50	Session 8: CAR T cells in ...
12:00-12:20	ALL: Jordan Gauthier , USA
12:20-12:40	CLL: Mohamed Kharfan-Dabaja , USA

12:40-13:00	Myeloma: Mohamad Mohty , France
13:00-13:20	Lymphoma: Anna Sureda , Spain
13:20-13:50	Panel Discussion
13:50-14:00	<i>Break</i>
14:00-15:30	Practical considerations in CAR-T therapy CME-accredited symposium Moderators: Mohamad Mohty , France & Arnon Nagler , Israel
14:00-14:20	Patient selection and timely referral: Michael Loschi , France
14:20-14:40	Safety of CAR-T cells in elderly lymphoma: Ron Ram , Israel
14:40-15:00	Prognostic features in large B-cell lymphoma patients receiving CAR T-cell therapy: Gloria Iacoboni , Spain
15:00-15:30	Panel Discussion
15:30-15:45	Closing Remarks: Mohamad Mohty , France & Arnon Nagler , Israel